Skip to main content
Equibles
RANI logo

RANI · Rani Therapeutics Holdings, Inc. · Metrics

Track RANI — free

Use RANI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RANI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.84 +0.02 (+2.51%) At close · Sep 11
Rebalance outlook locked
Market Cap
$117.45M
Shares
139.40M

RANI metrics

66 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.84
Market cap
$117.45M

Price action

20 metrics
Price change (1W)
-2.6%
Price change (30D)
+5.8%
Price change (3M)
+10.9%
Price change (6M)
-36.2%
Price change (YTD)
-37.6%
Price change (1Y)
+66.9%
Trailing year
Price change (5Y)
-95.8%
52-week high
$2.85
52-week low
$0.46
Change from 52-week high
-70.4%
Change from 52-week low
+84.0%
Annualized volatility
272.9%
Annualized volatility (3M)
80.9%
Beta
3.2
RSI (14D)
51.0
Price vs SMA 50
+5.5%
Price vs SMA 200
-20.7%
Avg volume (3M)
767,023
Relative volume
0.4
Average dollar volume
$616,159

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
139.40M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
24.1×
reciprocal yield 4.2%
P / book
3.0
reciprocal yield 33.4%
FCF yield
-17.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
72.2×
reciprocal yield 1.4%
EV / revenue historical average (5Y)
82.5×
reciprocal yield 1.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-26

Profitability

9 metrics
Gross margin
—
Operating margin
-675.8%
Trailing 12 months
Net margin
-505.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$32.96M
Net income (TTM)
−$24.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.13
FCF margin
-417.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+58.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.88M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+412.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+28.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.9%
Return on assets
-40.5%
Debt / equity
—
Current ratio
5.3
EBITDA (TTM)
−$32.24M
Free cash flow (TTM)
−$20.34M
Quick ratio
5.3
Interest coverage
-28.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.87M
Total assets
$60.84M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.29M
Capital expenditures (TTM)
$47,000
R&D (TTM)
$18.31M
SG&A (TTM)
—
Stock compensation (TTM)
$9.09M
R&D / revenue
375.4%
Stock compensation / revenue
186.4%

Ownership (13F)

3 metrics
13F filers
68
13F filer change QoQ
-8
Institutional ownership
32.8%

Short interest

3 metrics
Short interest
4.6%
Latest settlement · 8.1 days to cover
Days to cover
8.1d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
$50,033
Insider-sentiment score
84 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1856725 CUSIP 753018100 13F (30d) 22 filings 22 filers Visit website Investor relations